Could a 30-Year-Old blood vessel drug ease Parkinson's?
NCT ID NCT05931575
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether fasudil, a drug already used in Japan for blood vessel spasms, is safe and can help symptoms in people with early Parkinson's disease. 75 participants will take either fasudil or a placebo for 3 weeks. The study focuses on safety and tolerability, with a look at symptom changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fasudil hydrochloride
What this could lead to
If successful, this could point toward a new treatment option to ease symptoms of early Parkinson's disease.
What could go wrong
This is a small, early-phase trial (75 people, 3 weeks) focused on safety and tolerability, not proof of effectiveness. The drug may not improve symptoms or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PARKINSON´S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Technische Universität München, Klinikum rechts der Isar, Klinik und Poliklinik für Neurologie
Munich, 81675, Germany